- HLA-DM tetramers
- HLA-DQ8 tetramers for clinical usage
- SPR on artificial lipid membranes
- Characterization of recombinant CD3δε and γε
- Insulin peptide binding to MHC class II molecules
- In vitro activity of recombinant GLA and GLA on glycolipids
- CXCL4 binding to glycolipids
- Human proteome associated to glycolipid transport
- Treg cells in NOD mice and mutant NOD mice
- Changing the specificity of L363 antibodies
- Specificity of IVD12 and CS200.1 antibodies
- Role of the loop b40-50 in the allostery of MHC class II molecules
- Binding of HLA-DM to HLA-DQ8 and HLA-DQ2/8 transdimers
- Peptide binding to HLA-DQ8 dimers versus HLA-DQ2/8 transdimers
- Immune responses in HLA-DQ8 HuCD4 transgenic mice
- Immune responses in HLA-DR3-DQ2 HuCD4 transgenic mice
- Immune responses in HLA-DR3-DQ2-DQ8 HuCD4 transgenic mice
- Influence of CD3 for MHC class II tetramer binding
- Influence of lipid composition for MHC class II tetramer binding
- Redesign of MHC class II tetramers
- Reconstitution of the TCR-CD3 complex for structural studies
- Anti-gangliosides immune responses
- Role of glucosylceramide in thymic selection of NKT cells
- Enzymatic inhibitors to stimulate NKT cells
- Characterization of anti-glycan high affinity antibodies
- Crystallization of anti-glycan high affinity antibodies
- Monoclonal antibodies to alpha-linked monoglycosylceramides
- Characterization of CD32-TCR interactions
- Crispr/Cas9 disruption of lipid metabolism
- Characterization of anti-phospholipid antibodies
- Mapping of the binding sites of the invariant chain on MHC class II molecules
|
|
- Characterization of CD4+ autoreactive T cells in type 1 diabetes
- Designing and testing new anti-glycan based vaccines
- Using structural studies to produce a new class of immunosuppressive drugs
- Anti-HLA antibodies therapy in mouse model and pre-clinical studies
- Transport of glycolipids in human
- Manipulation of NKT cells in vivo for therapeutic applications
|
